Circadin® receives marketing authorization in Peru

Recent news

• Circadin® 2mg (prolonged-release melatonin) is now funded for insomnia in children and adolescents with Neurodevelopmental Disorders in New Zealand
• Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina
• Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Spain